Equities analysts predict that Opko Health Inc. (NASDAQ:OPK) will post earnings of ($0.07) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.03). Opko Health reported earnings of ($0.08) per share during the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The firm is scheduled to issue its next earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.20) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.06). For the next year, analysts anticipate that the company will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.21) to $0.10. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Opko Health.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Opko Health had a negative net margin of 15.46% and a negative return on equity of 7.69%. The company had revenue of $221.90 million during the quarter, compared to the consensus estimate of $242.05 million.
In related news, CEO Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock in a transaction dated Wednesday, April 17th. The stock was acquired at an average price of $2.42 per share, for a total transaction of $121,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $7,426,861.42. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of Opko Health stock in a transaction dated Thursday, January 31st. The shares were bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the transaction, the insider now directly owns 24,455,147 shares in the company, valued at approximately $194,662,970.12. The disclosure for this purchase can be found here. Insiders purchased 798,000 shares of company stock valued at $2,032,580 in the last quarter. 42.74% of the stock is owned by insiders.
Several large investors have recently modified their holdings of the company. Rhumbline Advisers raised its position in Opko Health by 40.8% in the 4th quarter. Rhumbline Advisers now owns 475,850 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 137,968 shares during the last quarter. Vanguard Group Inc raised its position in Opko Health by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Opko Health in the 4th quarter valued at $319,000. Strs Ohio raised its position in Opko Health by 27.0% in the 4th quarter. Strs Ohio now owns 112,500 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 23,900 shares during the last quarter. Finally, FMR LLC purchased a new stake in Opko Health in the 3rd quarter valued at $2,362,000. Institutional investors and hedge funds own 23.10% of the company’s stock.
Opko Health stock traded down $0.01 during trading on Tuesday, reaching $2.40. The stock had a trading volume of 6,731,012 shares, compared to its average volume of 3,690,665. Opko Health has a 52-week low of $2.34 and a 52-week high of $6.40. The company has a quick ratio of 0.96, a current ratio of 1.10 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.48 billion, a P/E ratio of -9.60 and a beta of 1.88.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.